Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Share Issue

Citi Appointed as Depositary Bank for Molecular Partners AG's ADR Programme


Citi, acting through Citibank N.A., has been appointed by Molecular Partners AG ("Molecular Partners"), a clinical-stage biotech company, to act as depositary bank for its American Depositary Receipt ("ADR") programme.

Molecular Partners' American Depositary Shares ("ADS") trade on the Nasdaq Global Market under the symbol "MOLN". Each ADS represents one ordinary share of the company.

Andreas Emmenegger, Molecular Partners' CFO, said: "We are pleased to be working with Citi as part of the team supporting our new Nasdaq listing."

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: "We look forward to supporting Molecular Partners' ADR programme and expanding the company's investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network."

For more information on Citi's Depositary Receipt Services, please visit www.citi.com/dr

About Molecular Partners

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi


These press releases may also interest you

19 mai 2024
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

19 mai 2024
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

19 mai 2024
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: